Neurona is a California-based biotechnology company that develops and commercializes stem cell-derived therapeutics for the treatment of neurological disorders.
Create an Alert for Neurona Therapeutics Jobs
Create a Job Alert
Get notified when new Neurona Therapeutics jobs are posted
Company Overview. Neurona Therapeutics is a clinical-stage biotechnology company based in South San Francisco focused on the development of allogeneic cell-based therapies for neurological diseases. Neurona’s lead product candidate, NRTX-1001, comprising GABAergic interneurons, offers a novel approach that is not tissue-destructive for the potential treatment of drug-resistant focal epilepsy. NRTX-1001 is currently being studied for safety and ef...
Company Overview. Neurona Therapeutics is a clinical-stage biotechnology company based in South San Francisco focused on the development of allogeneic cell-based therapies for neurological diseases. Neurona’s lead product candidate, NRTX-1001, comprising GABAergic interneurons, offers a novel approach that is not tissue-destructive for the potential treatment of drug-resistant focal epilepsy. NRTX-1001 is currently being studied for safety and ef...
(Onsite, South San Francisco – Bay Area). Company Overview. Neurona Therapeutics is a clinical-stage biotechnology company based in South San Francisco focused on the development of allogeneic cell-based therapies for neurological diseases. Neurona’s lead product candidate, NRTX-1001, comprising GABAergic interneurons, offers a novel approach that is not tissue-destructive for the potential treatment of drug-resistant focal epilepsy. NRTX-1001 is...
(Onsite, South San Francisco – Bay Area). Company Overview. Neurona Therapeutics is a clinical-stage biotechnology company based in South San Francisco focused on the development of allogeneic cell-based therapies for neurological diseases. Neurona’s lead product candidate, NRTX-1001, comprising GABAergic interneurons, offers a novel approach that is not tissue-destructive for the potential treatment of drug-resistant focal epilepsy. NRTX-1001 is...
